Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hematopoietic Stem Cell Transplantation, Graft-Versus-Host Disease”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00656058
What this trial is testing

Montelukast to Treat Bronchiolitis Obliterans

Who this might be right for
Bronchiolitis ObliteransChronic Graft Versus Host DiseaseLeukotriene+2 more
National Cancer Institute (NCI) 25
Testing effectiveness (Phase 2)WithdrawnNCT00002790
What this trial is testing

Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant

Who this might be right for
Graft Versus Host DiseaseLeukemiaMyelodysplastic Syndromes
Fred Hutchinson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT05600855
What this trial is testing

Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT Model

Who this might be right for
Transplant-Related Disorder
Institute of Hematology & Blood Diseases Hospital, China 115
Not applicableUnknownNCT00006055
What this trial is testing

Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases

Who this might be right for
Purpura, Schoenlein-HenochGraft Versus Host DiseaseAnemia, Hemolytic, Autoimmune+11 more
Fairview University Medical Center 10
Testing effectiveness (Phase 2)Ended earlyNCT00720629
What this trial is testing

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Who this might be right for
Graft Versus Host Disease
H. Lee Moffitt Cancer Center and Research Institute 8
Testing effectiveness (Phase 2)Study completedNCT01246206
What this trial is testing

Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT

Who this might be right for
Hematological Malignancies
Barbara Ann Karmanos Cancer Institute 21
Early research (Phase 1)WithdrawnNCT04361058
What this trial is testing

Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide

Who this might be right for
Leukemia, Myeloid, AcuteMyelodysplastic SyndromesMyelodysplastic Syndrome Acute Myeloid Leukemia
SCRI Development Innovations, LLC
Testing effectiveness (Phase 2)Looking for participantsNCT07216443
What this trial is testing

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Who this might be right for
Leukemia, Myeloid, AcuteMyelodysplastic SyndromesMixed Phenotype Acute Leukemia
Orca Biosystems, Inc. 80
Early research (Phase 1)Looking for participantsNCT06008808
What this trial is testing

Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Who this might be right for
Graft Vs Host DiseaseGraft-versus-host-diseaseGraft Versus Host Disease
Washington University School of Medicine 41
Testing effectiveness (Phase 2)Study completedNCT01244906
What this trial is testing

Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant

Who this might be right for
Hematologic Neoplasms
Northside Hospital, Inc. 26
Large-scale testing (Phase 3)Looking for participantsNCT06615050
What this trial is testing

Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

Who this might be right for
Graft-versus-host Disease (GVHD)
Incyte Corporation 572
Large-scale testing (Phase 3)Study completedNCT00438958
What this trial is testing

Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+3 more
The Canadian Blood and Marrow Transplant Group 230
Early research (Phase 1)Study completedNCT04539470
What this trial is testing

Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Who this might be right for
Acute Graft-versus-host Disease
Genentech, Inc. 18
Testing effectiveness (Phase 2)Looking for participantsNCT07359859
What this trial is testing

Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant

Who this might be right for
Hematologic Malignancies
Memorial Sloan Kettering Cancer Center 40
Not applicableUnknownNCT02300571
What this trial is testing

Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant

Who this might be right for
Hematological Malignancies
Fondazione del Piemonte per l'Oncologia 60
Testing effectiveness (Phase 2)Looking for participantsNCT05470491
What this trial is testing

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

Who this might be right for
HIVHematologic Malignancies
National Cancer Institute (NCI) 265
Testing effectiveness (Phase 2)Study completedNCT05311514
What this trial is testing

Allogeneic Platelet Lysate Eye Drops for the Treatment of Severe Chronic Ocular Graft-versus-host Disease

Who this might be right for
Ocular Graft-versus-host Disease
St. Petersburg State Pavlov Medical University 38
Testing effectiveness (Phase 2)Study completedNCT03990051
What this trial is testing

Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.

Who this might be right for
Chronic Ocular Graft-versus-host Disease
Glia, LLC 33
Testing effectiveness (Phase 2)Study completedNCT00423514
What this trial is testing

Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease

Who this might be right for
Graft Versus Host DiseaseLeukemiaMyelodysplastic Syndromes
Memorial Sloan Kettering Cancer Center 38
Testing effectiveness (Phase 2)Study completedNCT00357084
What this trial is testing

Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant

Who this might be right for
Cancer
Fred Hutchinson Cancer Center 53
Next Page